- Home
- ASIC vs CGEM Comparison
ASIC vs CGEM Comparison
Compare ASIC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASIC | CGEM |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.2M | 780.4M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASIC | CGEM |
|---|---|---|
| Price | $18.77 | $12.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $25.25 | ★ $28.33 |
| AVG Volume (30 Days) | 84.7K | ★ 665.8K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 504.00 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $405,657,000.00 | N/A |
| Revenue This Year | $14.72 | N/A |
| Revenue Next Year | $44.71 | N/A |
| P/E Ratio | $107.54 | ★ N/A |
| Revenue Growth | ★ 68.10 | N/A |
| 52 Week Low | $16.35 | $5.68 |
| 52 Week High | $25.30 | $13.43 |
Technical Indicators
Market Signals| Indicator | ASIC | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 56.93 |
| Support Level | $17.49 | $11.70 |
| Resistance Level | $19.18 | $13.43 |
| Average True Range (ATR) | 0.73 | 0.83 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 74.29 | 63.76 |
Price Performance
Historical ComparisonAbout ASIC Ategrity Specialty Insurance Company Holdings
Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.